Core Viewpoint - The company has achieved record-high gross margins, but short-term profits are impacted by foreign exchange losses and tax payments, maintaining a "Buy" rating [1] Group 1: Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.933 billion yuan, a year-on-year increase of 2.2%, and a net profit attributable to shareholders of 652 million yuan, up 9.27% year-on-year [1] - In Q3 2025, the company achieved revenue of 686 million yuan, a year-on-year increase of 14.86% and a quarter-on-quarter increase of 2.29%; net profit attributable to shareholders was 207 million yuan, a year-on-year increase of 7.72% but a quarter-on-quarter decrease of 17.58% [1] - The comprehensive gross margin for Q3 2025 was 55.62%, an increase of 4.42 percentage points year-on-year and 3.96 percentage points quarter-on-quarter [2] Group 2: Business Segments - The life sciences segment saw a revenue increase of 11% year-on-year, while the metal resources segment grew by 30% year-on-year, and the water treatment segment increased by 9% year-on-year; the food processing sector experienced a significant growth of 50% year-on-year [2] - The company is focusing on high-margin businesses, with the polypeptide solid-phase synthesis carrier business continuing to show good growth [2] Group 3: Future Growth Prospects - The company plans to invest 1.15 billion yuan to build a high-end materials industrial park for life sciences, which is expected to support future growth [3] - The company is expanding its life sciences business domestically and establishing a global marketing and technical service network [3] - New product developments in the life sciences sector include antibody IND applications and various types of chromatography fillers, which are anticipated to become new growth points for the company [3]

Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 1.933 billion CNY, a year-on-year increase of 2.20% [2] - The net profit attributable to the parent company was 0.207 billion CNY, reflecting a year-on-year growth of 9.27% [2] - Excluding the impact of large-scale lithium extraction project revenue, the revenue growth for the first three quarters was 8% [2] - In Q3 2025, the company reported operating revenue of 0.686 billion CNY, a year-on-year increase of 14.86% [2] - The overall gross profit margin for the reporting period was 52.81%, up by 4 percentage points year-on-year [3] Business Segments - Revenue from adsorption separation materials was 1.565 billion CNY, accounting for 80.95% of total revenue [4] - Revenue from system devices was 0.248 billion CNY, representing 12.83% of total revenue [4] - The company’s product structure has been optimized, with high-margin products in life sciences and metals showing significant growth [4] Growth Potential - The metal resources segment is one of the top three areas in the adsorption separation materials business, with ongoing expansion in the lithium industry chain [5] - The company has signed multiple industrial projects in nickel extraction, cobalt recovery, and vanadium extraction, indicating strong growth potential in the metal resources sector [5] Development Plans - The life sciences high-end materials industrial park will produce various products, including chromatography media and polymer chromatography fillers, with phased production based on market demand [6]

Core Viewpoint - The company reported a mixed performance for the first half of 2025, with revenue declining slightly while net profit increased, driven by high-margin product segments and improved operational efficiency [1][2]. Financial Performance - Revenue for H1 2025 was 1.247 billion yuan, a year-on-year decrease of 3.64% - Net profit attributable to shareholders was 445 million yuan, an increase of 10.01% - Operating cash flow showed a positive trend with a net cash flow of 288 million yuan, up 36.50% year-on-year [1]. Profitability - The company achieved a gross margin of 51.26% and a net margin of 35.97%, reflecting increases of 3.78 percentage points and 4.32 percentage points year-on-year, respectively - The improvement in profitability was attributed to a higher proportion of high-margin businesses in life sciences, metal resources, and ultra-pure water [1][2]. Business Segments - The company’s revenue from adsorption materials reached 1.007 billion yuan, a year-on-year growth of 3.40% - Key segments such as water treatment and ultra-pure water, life sciences, and metal resources reported revenues of 359 million yuan, 320 million yuan, and 149 million yuan, with year-on-year growth rates of 11.25%, 12.43%, and 22.84%, respectively [2]. Lithium Resource Development - The company has made significant progress in lithium extraction projects, with 12 projects completed or in execution, totaling nearly 100,000 tons of lithium carbonate/hydroxide capacity - The company is leading in lithium extraction technology and has established a benchmark project for "green zero-carbon direct lithium extraction" in Tibet [3]. Investment in Life Sciences - The company plans to invest 1.15 billion yuan in a high-end materials industrial park for life sciences in Pucheng, enhancing its capabilities in chromatography media and polymer chromatography fillers - The park will support the growth of various clinical-stage projects and has already seen positive feedback from international pharmaceutical companies [4]. Ultra-Pure Water Business - The company has increased its market penetration in the high-end drinking water sector and achieved significant breakthroughs in the ultra-pure water business - The ultra-pure water segment has secured substantial orders from leading semiconductor companies, indicating a strong market position [5]. Future Outlook - The company expects net profits attributable to shareholders to reach 1.014 billion yuan, 1.209 billion yuan, and 1.527 billion yuan for the years 2025 to 2027, with corresponding price-to-earnings ratios of 26.98X, 22.63X, and 17.92X [5].